Dr. Reddy`s Laboratories
Open
$15.38
Prev. Close
$15.38
High
$15.38
Low
$15.36
Market Snapshot
3.21
$13.4B
Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. The company is headquartered in Hyderabad, Telangana and currently employs 26,944 full-time employees. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. The company works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.
Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. The company is headquartered in Hyderabad, Telangana and currently employs 26,944 full-time employees. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. The company works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.
Recently from Cashu

Dr. Reddy's Laboratories Launches Generic Semaglutide Injection to Enhance Diabetes Treatment Access in Canada
Dr. Reddy's Laboratories (Ticker: RDY) launches a generic Semaglutide Injection in Canada, marking a significant milestone for the company in expanding its operations in the pharmaceutical landscape.…
Dr. Reddy's Laboratories and the Affordable Revolution of Semaglutide Pricing
Revolutionizing Access to Essential Medications: The Impact of Semaglutide Price Reductions Dr. Reddy's Laboratories faces a transformative moment in the pharmaceutical sector following the recent exp…
Collaborative Vaccine Development Initiative Targets Ebola, Benefits Dr. Reddy's Laboratories
Advancing Vaccine Development: A Collaborative Effort Against Ebola Dr. Reddy's Laboratories, a key player in the global pharmaceutical landscape, stands to benefit from the recent funding agreement a…
Dr. Reddy's Laboratories Navigates Competitive Challenges Amid Rivals' Legal Issues
Dr. Reddy's Laboratories Faces Competitive Landscape Amid Legal Challenges in the Industry Dr. Reddy's Laboratories, a prominent player in the global pharmaceutical sector, finds itself navigating a c…